"Spazgan" instruction refers to drugs of the combined type, to the group of antispasmodic and analgesic agents. Active components: metamizole sodium (non-narcotic analgesic), pitophenone hydrochloride (myotropic antispasmodic), fenpiverinium bromide (anticholinergic).
The latter, due to its anticholinergic properties, has an additional relaxing effect on smooth muscles in various organs. Pitophenone hydrochloride, similar to papaverine, has a direct myotropic effect on smooth muscles. Metamizole sodium, being a derivative of pyrazolone, has an antipyretic, analgesic and mild anti-inflammatory effect. Due to the combination of these components, their pharmacological properties are enhanced, which is reflected in a reduction in pain, relaxation of the smooth muscles of internal organs, and a decrease in elevated temperature.
Spazgan Instruction Indications.
The drug is used for mild or mild pain, accompanying a spasm of smooth muscles of the internal organs. Such conditions include intestinal, biliary, renal colic, dysmenorrhea and others. The "Spazgan" instruction allows for use for short-term therapy of neuralgia, joint pain, myalgia, sciatica. In the postoperative period and after diagnostic procedures, the drug may be prescribed in a complex to reduce the severity of pain. If necessary, the medication is used for infectious and inflammatory pathologies of a different nature to lower elevated body temperature.
Spazgan Instructions for use.
The drug is prescribed orally. Patients from the age of fifteen (adolescents and adults) are prescribed one or two tablets per day twice or thrice. It is allowed to receive no more than six tablets per day. Not more than five days - the duration of use. Patients from the age of twelve are recommended to take half a tablet, from thirteen to fifteen - a tablet two to three times a day.
The drug is contraindicated in disorders of renal and hepatic function, individual intolerance, tachyarrhythmias, congenital insufficiency of glucose-6-phosphate dehydrogenase. "Spazgan" is not prescribed for gastrointestinal obstruction, prostatic hypertrophy with a tendency to urinary retention. The drug is contraindicated in case of blood diseases, collapoid states, children under twelve years of age (for tablets), "Spazgan" during pregnancy (in the last six weeks, as well as in the first trimester) is also contraindicated. The drug is not recommended for lactation.
Taking the medication can cause a decrease in blood pressure, cyanosis, dizziness, tachycardia. Prolonged use provokes disorders of blood formation (agranulocytosis, leukopenia, thrombocytopenia). Some patients report allergic reactions in the form of itching, rash in rare cases - anaphylactic shock. "Spazgan" can cause an attack with a tendency to bronchospasm. In extremely rare cases, there is a headache, dry mouth, burning in the epigastrium.
"Spazgan" is prescribed with caution in cases of impaired renal and hepatic activity. Metabolites (decay products) of metomizole sodium can stain urine red.
The combined use of NSAIDs and "Spazgan" can cause a mutual increase in toxicity. Oral contraceptives, tricyclic antidepressants and allopurinol disrupt the metabolic process in the liver of metamizole, increasing its toxicity. The weakening of the action of this component is noted when taking phenylbutazone, barbiturates, and other inducers of microsomal liver enzymes. Tranquilizers, sedatives increase the severity of the analgesic effect.
As a rule, take "Spazgan" from a headache. According to consumer reviews, the drug acts quite quickly and effectively.